Alder Biopharmaceuticals Inc (ALDR): John A Latham , Chief Scientific Officer of Alder Biopharmaceuticals Inc sold 40,000 shares on May 27, 2016. The Insider selling transaction was reported by the company on Jun 1, 2016 to the Securities and Exchange Commission. The shares were sold at $30.04 per share for a total value of $1,201,619.12 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 1, 2016, Mark James Litton (Chief Business Officer) sold 25,000 shares at $30.05 per share price.On May 24, 2016, Randall C Schatzman (President and CEO) sold 10,000 shares at $28.02 per share price.Also, On Jan 6, 2016, John A Latham (Chief Scientific Officer) sold 10,000 shares at $31.55 per share price.On Dec 4, 2015, Jeffrey T L Smith (Sr. VP Translational Medicine) sold 4,272 shares at $37.24 per share price.
Alder Biopharmaceuticals Inc: On Wednesday, Jun 1, 2016 heightened volatility was witnessed in Alder Biopharmaceuticals Inc which led to swings in the share price. The shares opened for trading at $29.99 and hit $30.51 on the upside , eventually ending the session at $30.11, with a gain of 0.13% or 0.04 points. The heightened volatility saw the trading volume jump to 7,78,371 shares. The 52-week high of the share price is $54.9 and the company has a market cap of $1,505 M . The 52-week low of the share price is at $15.8201.
Company has been under the radar of several Street Analysts.Alder Biopharmaceuticals Inc is Resumed by Wells Fargo to Outperform. The Rating was issued on Apr 21, 2016.Alder Biopharmaceuticals Inc is Initiated by Brean Capital to Buy and the brokerage firm has set the Price Target at $45. The Rating was issued on Apr 20, 2016.
Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company discovers develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy as well as speed of onset and durability of therapeutic response. The Company’s pipeline includes ALD403 Clazakizumab and ALD1613. ALD403 is the Company’s monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6) and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH) and is being developed for the treatment of Cushing’s disease.